Topic

Feliza Mirasol is the science editor for 

Articles

uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.

uBriGene Expands into US Market with Acquisition of Mustang Bio's CGT Manufacturing Facility

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.

Waters Set for Growth in Bioanalytical Characterization with Wyatt Acquisition

This deal would help the companies merge to work on future projects and conduct research together.

SeraNovo and AstraZeneca Collaborate on Future Research Projects

Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio, which will occur at Forge’s gene therapy facility in Columbus, Ohio called the Hearth.

Life Biosciences, Forge Biologics Partner for Manufacturing to Advance Gene Therapies

 This approach is defined as being used to express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs).

Research Collaboration for Mekonos, Bit.bio to Advance Cell Engineering 


The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.

Cellular Origins Collaborates with ScaleReady for Cell and Gene Therapies

Critical raw materials supplier, Biosynth, has acquired UK-based Cambridge Research Biochemicals (CRB).

Biosynth Acquires Cambridge Research Biochemicals

The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.

PI Healthsciences Acquires Archimica S.p.A from Livia Group

The new agreement is based off the Master Services Agreement that both companies entered in 2021 for the development, manufacture, and supply of rhenium (186Re) obisbemeda, according to a press release.

Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions 

Presspart will still be responsible for the manufacturing of the Sunriser device.

Mergers and Acquisitions